#USA #Phoenix #NSCLC #OncoC4 #Cesalatamig

OncoC4's Breakthrough in Non-Small Cell Lung Cancer Treatment

On November 6, 2026, OncoC4 Inc. announced groundbreaking results from their Phase 1/2 clinical trials on cesalatamig, an investigational bispecific antibody targeting PD-1 and VEGF. This therapy is significant for patients with non-small cell lung cancer (NSCLC) who have already undergone treatment with PD-(L)1-targeting immunotherapy and chemotherapy, making it a pivotal advancement in a field where options are severely limited.

The study was conducted as part of the BiPAVE-001 and BiPAVE-001 CN trials, which included over 100 patients with varying histological types of NSCLC. Among these patients, a considerable percentage had undergone multiple lines of therapy, setting a challenging scenario for treatment. The results were impressive: the study reported a 33% objective response rate and a staggering 90% disease control rate at the highest dosage of 10 mg/kg administered every three weeks.

Study Findings

Investigating the effects of cesalatamig across a range of dosages revealed encouraging outcomes. In the cohort of 55 patients deemed evaluable for efficacy, those receiving 10 mg/kg dosage experienced a 33% objective response rate, as judged by investigators. This was contrasted with lower rates observed at doses of 1 mg/kg and 3 mg/kg, which demonstrated response rates of 10% and 21%, respectively. Moreover, disease control rates consistently improved with increasing doses, making the case for a more robust dosage during treatment—a crucial factor for enhancing patient outcomes.

Notably, the safety profile of cesalatamig remained manageable across all dosage levels, which is essential for patients who often have diminished health due to previous treatments. Dr. Kai He, the lead investigator of the US BiPAVE-001 trial, expressed optimism, emphasizing that the responses observed with cesalatamig are promising and lay the groundwork for further clinical evaluations.

Dr. Yang Liu, co-founder and CEO of OncoC4, further reinforced the potential of cesalatamig, stating that these clinical results support advancing this therapy for previously treated NSCLC patients. Given the FDA's Fast Track designation for cesalatamig, the company is primed to pursue pivotal studies to solidify its therapeutic applications.

Next Steps for Clinical Development

With these promising results, OncoC4 is set to build upon these findings as they prepare for further clinical evaluations of cesalatamig in NSCLC. The company is focusing on confirming the efficacy of the 10 mg/kg dosage, which they believe provides a clear pathway for pivotal trials. The ongoing BiPAVE-001 clinical program is critical for validating cesalatamig’s capabilities and assessing its impact on patients suffering from this aggressive disease.

In summary, OncoC4's recent developments regarding cesalatamig highlight a beacon of hope for NSCLC patients who have exhausted traditional treatment options. The encouraging Phase 1/2 data serves not only as a testament to the innovative research being carried out but also sets a promising precedent for future oncology therapies.

For more insights and updates on OncoC4 and cesalatamig’s journey, you can follow their announcements as they prepare for the upcoming late-breaking presentation at the Society for Immunotherapy of Cancer (SITC) 2026, scheduled in Phoenix, Arizona.